ERYTECH announces its participation in january
at virtual investor conferences
Lyon, France), and Cambridge, MA (U.S.) the January 03 2022 – ERYTECH Pharma (Euronext : ERYP ; Nasdaq : ERYP), company clinical stage biopharmaceutical that develops innovative therapies by encapsulating drugs in red blood cells (GR), announcement today sat participation at the following investor conferences during the month of January and offers investorss individual meetings.
LifeSci Partners – 11th Annual Corporate Access Event
Wednesday January 5 – Friday January 7 Registration link
To propose an individual meeting Click here
HC Wainwright BioConnect Virtual Conference
Monday January 10 – Thursday January 13 Registration link
A webcast will be available for 90 days in the Webcasts section of the ERYTECH website on January 10 at 1:00 p.m. KST or by using the following link:
https://journey.ct.events/view/eedb95cb-c2c2-4543-9cfb-f73edb3b12c6
If you would like to arrange a one-on-one meeting, please contact the conference representative.
About ERYTECH and eryaspase (GRASPA®) www.erytech.com
Founded in Lyon in 2004, ERYTECH is a clinical stage biopharmaceutical company that develops innovative therapies based on red blood cells to fight cancer and orphan diseases. By relying on its proprietary ERYCAPS® platform, an innovative technology allowing the encapsulation of drugs in red blood cells, ERYTECH is developing a portfolio of product candidates targeting markets with significant unmet medical needs.
ERYTECH mainly focuses on the development of products targeting metabolic disturbances in cancer cells, in order to deprive them of the amino acids necessary for their growth and survival.
The Company’s flagship product, eryaspase (GRASPA®), consisting of L-asparaginase encapsulated in red blood cells from donors, attacks the altered metabolism of asparagine and glutamine in cancer cells. The proof of concept of eryaspase as a metabolic agent against cancer has been established in different trials in acute lymphoblastic leukemia (ALL) and pancreatic cancer. A researcher-sponsored phase 2 study (STI) evaluating the use of eryaspase in patients with ALL who developed hypersensitivity reactions to pegylated asparaginase recently yielded positive results, based on which the Company intends to file for approval in the United States and potentially other jurisdictions. Eryaspase is also being evaluated in a phase 1 clinical trial sponsored by researchers in the first-line treatment of advanced pancreatic cancer.
Eryaspase has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity reactions to pegylated asparaginase and for the treatment of cancer of the breast. advanced pancreas. The FDA and the European Medicines Agency have granted orphan drug status to eryaspase for the treatment of ALL and pancreatic cancer.
ERYTECH produces its drug candidates for the treatment of patients in Europe at its GMP-compliant production site in Lyon, France, and for patients in the United States at its GMP-compliant production site in New Jersey, United States. Eryaspase is not approved in any country.
ERYTECH is listed on the Nasdaq Global Select Market in the United States (symbol: ERYP) and on the regulated market Euronext in Paris (ISIN code: FR0011471135; symbol: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indices.
CONTACTS
| ERYTECH Eric Soyer Chief Financial Officer and Chief Operating Officer | NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor Relations Nicolas merigeau Media Relations | LifeSci Advisors, LLC Investor Relations Corey Davis, Ph.D. |
| +33 (0) 4 78 74 44 38 [email protected] | +33 (0) 1 44 71 94 94 [email protected] | +1 (212) 915 – 2577 [email protected] |
Forward-looking statements
This press release contains forward-looking statements, including with respect to the clinical development and regulatory strategy of eryaspase, including the timing of BLA’s potential submission to the FDA for the treatment of acute lymphoblastic leukemia, the ability of the company to obtain regulatory approval for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity reactions to asparaginase-derivedE.coli, the ability of the company to expand the scope of eryaspase indication, the ability of the company to obtain additional funds under the OCABSA financing agreement or other financing attempts, and the anticipated cash flow of the society. Some of these statements, forecasts and estimates may be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “plans”, “plans”, “seeks”, “Esteem”, “may”, “will” and “continue” and other similar expressions. Such statements, forecasts and estimates are based on various assumptions and assessments of risks, uncertainties and other known and unknown factors, which were believed to be reasonable when made, but which may not turn out to be correct. Actual events are difficult to predict and may depend on factors that are beyond the control of the company. With respect to the portfolio of product candidates, there can be no assurance that these product candidates will receive the necessary regulatory approvals or that they will achieve commercial success. Society’s expectations regarding the effects of COVID-19 on society’s testing and development may be incorrect. Therefore, actual results and schedule may turn out to be materially different from anticipated future results, performance or achievements as expressed or implied by such statements, forecasts and estimates. The documents filed by ERYTECH with the Autorité des Marchés Financiers (AMF) and the Securities and Exchange Commission (SEC), including the 2020 Universal Registration Document of the Company registered with the AMF on March 8, 2021, on Company Annual Report (Form 20-F) filed with the SEC on March 8, 2021 and future Company registrations and reports, describe these risks and uncertainties. In view of these uncertainties, no representation is made as to the accuracy or fairness of these forward-looking statements, forecasts and estimates. In addition, forward-looking statements, forecasts and estimates speak only as of the date of this press release. Readers are therefore urged not to place undue reliance on these forward-looking statements. ERYTECH disclaims any obligation to update these forward-looking statements, forecasts or estimates in order to reflect any change in the company’s expectations with regard to them, or any change in the events, conditions or circumstances on which these statements, forecasts or estimates are based, except as required by law. In addition, the COVID-19 pandemic and all the measures that have been taken to mitigate its impacts are negatively affecting the economy, for a duration and severity that remain uncertain. Government measures to stabilize the situation will not be able to completely mitigate the consequences. The extent and duration of these impacts on the Company’s activity and results are very uncertain, and these impacts may in particular affect the Company’s clinical developments, as well as its supply chain. Factors impacting the business and results of the company include the duration and extent of the pandemic, the extent of mandatory containment and mitigation measures for the effects of the pandemic, and the consequences of the pandemic. on the economy in general. The pandemic could have negative effects on the activity of the company, the progress of its projects and its financial results for a longer period.
220103 ERYTECH_CP_Jan 2022 Conferences Investisseurs_vf
